Zobrazeno 1 - 10
of 13
pro vyhledávání: '"K. Hulst"'
Jonge zuigelingen en kinderen hebben soms problemen met eten, drinken en/of slikken. De oorzaken daarvoor variëren sterk, van vroeggeboorte, anatomische of motorische problemen in het mondgebied tot langdurige sondevoeding en lichamelijke aandoening
Publikováno v:
Clinical Pharmacology and Therapeutics. 56:389-397
The pharmacokinetic interaction between phenytoin and tirilazad was studied in 12 healthy men who received 200 mg phenytoin orally every 8 hours for 11 doses and 100 mg for the remaining 5 doses in one period of a two-way crossover study. In both per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9b104701cb71e0b925a98d284cefa57
https://doi.org/10.1038/clpt.1994.153
https://doi.org/10.1038/clpt.1994.153
Publikováno v:
The Journal of Clinical Pharmacology. 34:837-841
The potential interaction between tirilazad mesylate, a membrane lipid peroxidation inhibitor, and nimodipine, a calcium-channel antagonist, was assessed in 12 healthy male volunteers. Subjects received 60 mg nimodipine orally, 2.0 mg/kg tirilazad me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2563ff0d6d25d05a7ba41a54a9642c53
https://doi.org/10.1002/j.1552-4604.1994.tb02048.x
https://doi.org/10.1002/j.1552-4604.1994.tb02048.x
Autor:
John D Harry, Joseph C. Fleishaker, G.R. Peters, Penelope Ward, D Mark Wright, Laura K. Hulst
Publikováno v:
Clinical Pharmacology and Therapeutics. 55:378-384
Tirilazad mesylate pharmacokinetics were assessed in 12 young and 12 elderly volunteers (six men and six women per age group). Subjects received single 10-minute intravenous infusions of 1.5 mg/kg and 3.0 mg/kg tirilazad mesylate. Plasma tirilazad me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::818138d8608792196ddcb4e3547846fc
https://doi.org/10.1038/clpt.1994.45
https://doi.org/10.1038/clpt.1994.45
Publikováno v:
Pharmaceutical Research. 11:341-344
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a087bdda128fb31700bd0673fb9b74
https://doi.org/10.1023/a:1018988331700
https://doi.org/10.1023/a:1018988331700
Publikováno v:
Drug Investigation. 4:155-165
Adinazolam, a triazolobenzodiazepine, has been studied in the treatment of depression, panic disorder and anxiety. N-Desmethyladinazolam (NDMAD), the primary metabolite of adinazolam, produces benzodiazepine-like psychomotor effects after adinazolam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1da6e9bd175c8ca7101f8f1923cce177
https://doi.org/10.1007/bf03258394
https://doi.org/10.1007/bf03258394
Publikováno v:
American journal of therapeutics. 2(8)
The pharmacokinetics of tirilazad were assessed in men ages 40--60 years, women
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60d75341701a1178d6be28d4d83c73de
https://pubmed.ncbi.nlm.nih.gov/11854826
https://pubmed.ncbi.nlm.nih.gov/11854826
Publikováno v:
International journal of clinical pharmacology and therapeutics. 32(5)
Multiple dose pharmacokinetics and tolerability of tirilazad mesylate were assessed at the maximum dosage and duration expected for tirilazad mesylate therapy of subarachnoid hemorrhage and head injury. Healthy male subjects (47) received either 1 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::98066dd5e9e7987815d455f9005e8a80
https://pubmed.ncbi.nlm.nih.gov/7921515
https://pubmed.ncbi.nlm.nih.gov/7921515
Publikováno v:
Pharmaceutical research. 11(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::319750b1e70676599b3d0851b9ab3dd9
https://pubmed.ncbi.nlm.nih.gov/8165199
https://pubmed.ncbi.nlm.nih.gov/8165199
Autor:
Joseph C. Fleishaker, L. K. Hulst
Publikováno v:
European Journal of Clinical Pharmacology. 46
We have assessed the pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzo-diazepine. Healthy men took fluvoxamine maleate daily for 10 days (50 mg on days 1-3, 100 mg on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4470aadf2b70e67c749f3d515cf4bc21
https://doi.org/10.1007/bf00195913
https://doi.org/10.1007/bf00195913